Meeting
2019 ASCO Quality Care Symposium
Impact of in-house specialty pharmacy on access to novel androgen axis inhibitors in men with advanced prostate cancer.
Authors
Nathan Handley
Thomas Jefferson University, Philadelphia, PA
Nathan Handley, Siobhan Kirk, Anna Driscoll, Adam Binder, William Kevin Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cost, Value, and Policy; Health Equity and Disparities
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities
Sub Track
Access to Care
Citation
J Clin Oncol 37, 2019 (suppl 27; abstr 132)
DOI
10.1200/JCO.2019.37.27_suppl.132
Abstract #
132
Poster Bd #
L1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Quality of treatment with targeted agents for advanced prostate cancer by treating specialist.
First Author: Kassem S Faraj
Poster
2021 Genitourinary Cancers Symposium
Evaluating financial burdens of oral hormonal therapies for patients with prostate cancer.
First Author: Eric B Schwartz
Poster
2024 ASCO Genitourinary Cancers Symposium
Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.
First Author: David Joseph Benjamin
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan